Mayzent (Siponimod) vs Lyvispah (baclofen)

Mayzent (Siponimod) is a sphingosine 1-phosphate receptor modulator approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It works by trapping immune cells in lymph nodes, preventing them from reaching the central nervous system and causing nerve damage. In contrast, Lioresal/Lyvispah (baclofen) is a muscle relaxer and an antispastic agent used to treat muscle symptoms caused by multiple sclerosis, including spasm, pain, and stiffness, but it does not alter the course of the disease. When deciding between the two, a patient with MS should consider that Mayzent addresses the underlying disease processes of MS, potentially slowing progression, while baclofen is symptomatic treatment aimed at relieving muscle-related symptoms. The choice of medication would depend on the individual's specific symptoms and disease course, and it should be made in consultation with a healthcare professional.

Difference between Mayzent and Lyvispah

Metric	Mayzent (Siponimod)	Lyvispah (baclofen)
Generic name	Siponimod	Baclofen
Indications	Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease	Spasticity from multiple sclerosis, spinal cord injuries, or other spinal cord diseases
Mechanism of action	Sphingosine 1-phosphate receptor modulator	GABA-B receptor agonist
Brand names	Mayzent	Lyvispah, Lioresal, Gablofen
Administrative route	Oral	Oral, Intrathecal
Side effects	Headache, hypertension, liver function test abnormalities, bradycardia	Drowsiness, dizziness, weakness, fatigue, headache, insomnia, nausea, increased urination
Contraindications	CYP2C93/3 genotype, recent myocardial infarction, stroke, heart failure, certain immunosuppressive therapies	Hypersensitivity to baclofen, patients with epilepsy, history of stroke, or renal impairment
Drug class	Sphingosine 1-phosphate receptor modulator	Antispastic agent
Manufacturer	Novartis	Various, including Novartis for the brand Lioresal

Efficacy

Mayzent (Siponimod) and Its Efficacy in Multiple Sclerosis

Mayzent (Siponimod) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS), specifically for relapsing forms of the disease, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The efficacy of Mayzent in treating MS is attributed to its mechanism of action as a sphingosine 1-phosphate receptor modulator, which is thought to work by trapping immune cells in lymph nodes, preventing them from reaching the central nervous system and causing damage. Clinical trials have shown that Mayzent can reduce the rate of relapses and slow the progression of disability in individuals with relapsing forms of MS.

One pivotal phase III trial, the EXPAND study, demonstrated that Siponimod significantly reduced the risk of three-month confirmed disability progression compared to placebo in patients with secondary progressive multiple sclerosis (SPMS). Furthermore, Siponimod also had a positive impact on annualized relapse rates and MRI findings, such as reducing the number of new or enlarging lesions, which are important markers of MS disease activity.

Lyvispah (Baclofen) and Its Efficacy in Multiple Sclerosis

Lyvispah (baclofen) is a medication that is commonly used off-label for the management of spasticity in patients with multiple sclerosis. Although not specifically approved for MS, baclofen's efficacy in this condition has been recognized through its widespread use and supportive clinical evidence. Baclofen acts as a muscle relaxant by activating the GABA-B receptors, which leads to decreased excitability of nerve cells and thus reduces muscle spasticity. For individuals with MS, this can translate to improvements in muscle stiffness, spasms, and pain, which are common symptoms associated with the disease.

Clinical studies and patient reports have indicated that baclofen can significantly improve the quality of life for patients with MS by enhancing mobility and reducing discomfort caused by spasticity. However, the response to baclofen can be variable among patients, and it requires careful dose titration to balance efficacy with potential side effects. While baclofen is widely used for spasticity in MS, its use should be individualized, and patients should be monitored closely by healthcare professionals to optimize treatment outcomes.

Regulatory Agency Approvals

Mayzent

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Lyvispah

Food and Drug Administration (FDA), USA

Access Mayzent or Lyvispah today

If Mayzent or Lyvispah are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Mayzent

Buy Lyvispah

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: